Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 1/20 | 0.71 |
| ▸ | CDK8 | P49336 | 1/20 | 0.71 |
| ▸ | GAK | O14976 | 3/20 | 0.61 |
| ▸ | ALK | Q9UM73 | 6/20 | 0.56 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.55 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.55 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.53 |
| ▸ | FADS1 | O60427 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | KDR | P35968 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23999712 | 0.84 | DNMT1 (0.69) | CCNCCDK8MAPKAPK2 | |
| SCHEMBL24006270 | 0.84 | CCNC (0.59) | CCNCCDK8GAKTGFBR1ERBB2 | |
| SCHEMBL4740996 | 0.84 | FADS1 (0.71) | CCNCCDK8GAKTGFBR1ERBB2 | |
| SCHEMBL24003994 | 0.83 | MAPKAPK2 (0.67) | CCNCCDK8GAKERBB2MAPKAPK2 | |
| SCHEMBL28989120 | 0.83 | CDK8 (0.58) | CCNCCDK8GAKALKTGFBR1 | |
| SCHEMBL24006287 | 0.83 | DNMT1 (0.55) | CCNCCDK8GAKTGFBR1MAPKAPK2 | |
| SCHEMBL25825392 | 0.82 | DNMT1 (0.54) | CCNCCDK8GAKMAPKAPK2 | |
| SCHEMBL30290755 | 0.82 | DNMT1 (0.68) | CCNCCDK8TGFBR1EGFR | |
| SCHEMBL24005986 | 0.82 | DNMT1 (0.74) | CCNCCDK8 | |
| SCHEMBL24011122 | 0.82 | DNMT1 (0.68) | CCNCCDK8TGFBR1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240092800-A1 | USP13 INHIBITORS AND METHODS OF USE THEREOF | GEORGETOWN UNIVERSITY (US) | 2024-03-21 | — | — | US | disclosed |
| US-20230219927-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092800-A1 | USP13 INHIBITORS AND METHODS OF USE THEREOF | USP13, USP3, USP1 | CCNC 1813/4885CDK8 567/4885GAK 617/4885 |
| US-20230219927-A1 | AKT3 MODULATORS | AKT3, AKT2, PIK3CA | CCNC 491/4885CDK8 385/4885GAK 493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.